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Current guidelines recommend three drug combinations
to treat antiretroviral naïve HIV-infected patients; some
data of novel strategies with NRTI-sparing regimen in this
setting are now available [1,2]. The study compares immu-
novirological efficacy and safety of once daily maraviroc
(MVC) plus lopinavir/ritonavir (LPV/r) to tenofovir/emtri-
citabine (TDF/FTC) plus LPV/r.
This is an ongoing, proof-of-concept, randomized, open-
label, 48 weeks trial. Data were collected at baseline (BL)
and at 4, 12 , 24, 36 and 48 weeks. Comparisons between
groups evaluated by the chi-square or Mann-Whitney
rank-sum test. Results reported as median (Q1-Q3) or fre-
quency (%), as appropriate.
Up to date, 13 pts (7 MVC, 6 TDF/FTC) reached week
24 (W24), 10 (5 MVC, 5 TDF/FTC) week 12 (W12), 1
(MVC) week 4 (W4) without modification of the initial
regimen; age 41.1 (41.7-49.9) years, 1/24 (4%) female,
infected since 3.8 (2.3-7.6) years, CD4 nadir 266 (240-321)
cells/µL. At BL: CD4 284 (260-325) cells/µL; CD4% 17.6
(13.9-22.5), HIV-RNA 4.3 (3.9-4.9) log10 copies/mL. No
difference in BL characteristics were found between the
two treatment groups.
At W24, all patients in both groups had HIV-RNA<50
copies/ml; decrease in viral load was similar in both
groups at each timepoint. CD4 cells count increased in
both groups, more rapidly in MVC group and was simi-
lar at week 12 and week 24, possibly due to the small
number of subjects [CD4 change at W4: MVC group
183(134-225); TDF/FTC group 60(25-147), p=0.027; at
W12: MVC group 161.5(141.5-216); TDF/FTC group
122(53.5-203), p=0.087; at W24: MVC group 174(72-
179); TDF/FTC group 171(53.5-203), p=0.158].
Treatment was well tolerated, without grade 3 or 4
adverse events. No significant differences between the two
groups were observed in bone marrow function, AST,
ALT and CPK values, creatinine value, glucose profile
(fasting glucose and insulin) and lipid profile (total choles-
terol, LDL and HDL cholesterol) expect for triglycerides
that significantly increased in TDF/FTC group [W24
increase in MVC group: 40 mg/dl (-3-299); TDF/FTC
group: 119 (-29-137), p=0.037].
In this small sample size, NRTIs-sparing regimen with
Maraviroc QD and lopinavir/ritonavir is similar in efficacy
and tolerability to conventional treatment in naïve-
patients. A more favourable trend in immunological recov-
ery was observed but it needs to be confirmed in larger
samples. Regimens NRTIs-sparing in HIV-infected
patients naïve to antiretroviral therapy should be explored.
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